Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Replicel Life Sciences Inc
V.RP
Alternate Symbol(s):
REPCF
Technology
Scientific & Technical Instruments
RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair...
restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:RP)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
...
Next
(12)
•••
MetzGER
X
View Profile
View Bullboard History
Comment by
MetzGER
on Aug 18, 2022 9:56am
RE:AUG 24 AGM cancelled
It is obvious that they cancelled AGM in August because it Makes more Sense to do AGM After the Next Big Shiseido Deal in october
(2139)
•••
lscfa
X
View Profile
View Bullboard History
Post by
lscfa
on Aug 17, 2022 4:47pm
AUG 24 AGM cancelled
per sedar
Level Up Your Trading with BMO InvestorLine’s Enhanced Features
posted Nov 24, 2024 9:00am by
Bank of Montreal
-
|
Features like Multi-Leg Orders, Options Screener, and Strategy Builder will be particularly exciting for traders. They have been designed to be intuitive and user-friendly, regardless of your experience level. Whether you’re a seasoned pro or just starting out, you’ll find these tools easy to navigate and adapt to your investing style. ...read more
(55)
•••
Ingiboy
X
View Profile
View Bullboard History
Comment by
Ingiboy
on Aug 16, 2022 7:57pm
RE:ready to rock??
Yes a little volume is good to see. It is very capable of making a good move with some "real" news. Today may have been some early anticipation of what is come come shortly
(15)
•••
bluemoons20
X
View Profile
View Bullboard History
Post by
bluemoons20
on Aug 16, 2022 5:41pm
ready to rock??
up 14% today. best climb in a long time. Time for a huge move!! GLTA
(55)
•••
Ingiboy
X
View Profile
View Bullboard History
Comment by
Ingiboy
on Aug 15, 2022 10:28am
RE:RE:RE:RE:Shiseido Arbitration
This from Twitter Oct. 17th 2020: " RepliCel Life Sciences Inc.
...more
(55)
•••
Ingiboy
X
View Profile
View Bullboard History
Comment by
Ingiboy
on Aug 13, 2022 9:54am
RE:RE:RE:Shiseido Arbitration
Are you speculating they might be working on a deal or have you heard somethng ? One thing we forget about is Replicel I assume has patents surrounding RCH-01. One way or another Shiseido
...more
(4)
•••
Genie29j
X
View Profile
View Bullboard History
Comment by
Genie29j
on Aug 12, 2022 11:34pm
RE:RE:Shiseido Arbitration
The amount of time this is taking with Shiseido - I feel is a good sign 1. If this was dead upon arrival, I think we would have heard by now 2. Replicel clearly is putting up a fight. 3.
...more
(12)
•••
MetzGER
X
View Profile
View Bullboard History
Comment by
MetzGER
on Aug 10, 2022 9:18am
RE:Shiseido Arbitration
This 2 months waiting wont kill us anymore. I am waiting For 4 Years so 2 months is No Problem For me
(55)
•••
Ingiboy
X
View Profile
View Bullboard History
Post by
Ingiboy
on Aug 09, 2022 8:34pm
Shiseido Arbitration
We are 9 days away from 10 months with the Shiseido Arbitration. I am dumbfounded that a simple dispute over did one, both or neither of these companies break the contract. I am sure they
...more
(69)
•••
Humanist
X
View Profile
View Bullboard History
Comment by
Humanist
on Aug 05, 2022 4:34pm
RE:NR's
ive been watching this stock for quite some time.. do you happen to know if there is a scheduled arbitration, court, etc... of any type between the 2 .. thx sheseido is the the
...more
(55)
•••
Ingiboy
X
View Profile
View Bullboard History
Post by
Ingiboy
on Aug 05, 2022 2:06pm
NR's
The 3 NR's from this past week show progress in locking down patents for Dermaprecise as well as showing the market that the injection device is getting closer to submission for FDA and CE Mark
...more
(69)
•••
Humanist
X
View Profile
View Bullboard History
Comment by
Humanist
on Aug 05, 2022 8:43am
RE:Patent US11311684B2
hey iscfa, i see youre in this one or watching it, i ve had it on my watch list for along time.. what devices of prior art are you referring to? and are you being positive about the recent NR about
...more
(2139)
•••
lscfa
X
View Profile
View Bullboard History
Post by
lscfa
on Aug 04, 2022 9:05am
Patent US11311684B2
However, none of the devices of the prior art allows the delivery of liquid substances, such as cells, without the application of pressure or shear-stress. Furthermore, none of the devices of the
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Aug 04, 2022 6:00am
New Press Release - RepliCel Announces Material Patent Milestones in Key Markets
New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key marketsVANCOUVER, BC / ACCESSWIRE / August 4, 2022 / RepliCel Life Sciences Inc. (OTCPK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing novel, next...
read article.
Prev
...
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >